FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2026年2月26日 | 6,373,467,624 | | 5,534,650 | | 6,379,002,274 | | 1). 購回股份 (股份被持作庫存股份) ...

Core Insights - The top three companies with the highest short positions as of February 20 are China COSCO Shipping (01919) at 18.86%, CATL (03750) at 16.68%, and Ping An Insurance (02318) at 15.48% [1][2] Group 1: Top Short Positions - China COSCO Shipping (01919) has a short position of 520 million shares, representing a short ratio of 18.86% [2] - CATL (03750) has a short position of 26.0064 million shares, with a short ratio of 16.68% [2] - Ping An Insurance (02318) has a short position of 1.153 billion shares, with a short ratio of 15.48% [2] - Sunny Optical Technology (02382) has a short ratio of 15.24% [2] - Dongfang Electric (01072) has a short ratio of 15.12% [2] - ZTE Corporation (00763) has a short ratio of 14.53% [2] - Vanke (02202) has a short ratio of 14.16% [2] - Zijin Mining (02899) has a short ratio of 13.50% [2] - Hansoh Pharmaceutical (01276) has a short ratio of 13.32% [2] - WuXi AppTec (02359) has a short ratio of 12.50% [2] Group 2: Largest Increases in Short Positions - Weimob (02013) saw an increase of 0.27% in its short ratio, now at 12.43% [2] - China Duty Free Group (01880) increased by 0.25%, now at 8.92% [2] - Midea Group (00300) increased by 0.23%, now at 4.26% [2] - Meitu (01357) increased by 0.22%, now at 8.21% [2] - Xinjiang Xinxin Mining (03833) increased by 0.20%, now at 0.51% [2] - Hua Hong Semiconductor (01347) increased by 0.20%, now at 3.59% [2] - Minmetals Development (00425) increased by 0.19%, now at 2.59% [2] - China COSCO Energy (01138) increased by 0.18%, now at 6.61% [2] - Jiaxin International Resources (03858) increased by 0.17%, now at 0.25% [2] - China Railway (00390) increased by 0.17%, now at 4.61% [2] Group 3: Largest Decreases in Short Positions - Pacific Basin Shipping (02343) decreased by 0.83%, now at 4.66% [3] - Tianqi Lithium (09696) decreased by 0.66%, now at 2.25% [3] - Tiangong International (00826) decreased by 0.51%, now at 3.46% [3] - Huiju Technology (01729) decreased by 0.50%, now at 3.08% [3] - Shengye (06069) decreased by 0.44%, now at 1.63% [3] - Ganfeng Lithium (01772) decreased by 0.29%, now at 8.52% [3] - China Galaxy (06881) decreased by 0.25%, now at 3.19% [4] - Jiangxi Copper (00358) decreased by 0.22%, now at 2.32% [4] - China COSCO Shipping (01919) decreased by 0.21%, now at 18.86% [4] - Cafe de Coral (00341) decreased by 0.19%, now at 5.43% [4]

Group 1 - The core point of the article is that Heng Rui Pharmaceutical conducted a block trade on February 27, with a total of 75,100 shares traded, amounting to 4.2477 million yuan, which represents 0.21% of the total trading volume for that day [1][2] - The transaction price was 56.56 yuan per share, which remained unchanged compared to the market closing price of 56.56 yuan [1][2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 呈交日期： 2026年2月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- ...

Group 1 - The company, Heng Rui Medicine (01276.HK), announced a share buyback on February 26, 2026, spending RMB 15.6303 million to repurchase 276,000 A-shares [1] - The buyback price ranged from RMB 56.61 to RMB 56.69 per share [1]

Group 1 - The company Heng Rui Medicine (600276) announced a share buyback plan on February 26, 2026, with an investment of 15.6303 million yuan to repurchase 276,000 A-shares [1]

Group 1 - The company, Heng Rui Medicine (stock code: 01276), announced a share buyback plan [1] - The company will spend 15.6303 million yuan to repurchase 276,000 A-shares [1] - The buyback is scheduled to take place on February 26, 2026 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 呈交日期： 2026年2月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- ...

Core Viewpoint - Heng Rui Medicine's stock price has experienced a decline of 4.82% year-to-date, with significant drops over various trading periods, indicating potential challenges in market performance [2]. Group 1: Stock Performance - As of February 26, Heng Rui Medicine's stock price was 56.70 CNY per share, with a trading volume of 21.67 billion CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 376.33 billion CNY [1]. - The stock has decreased by 4.82% since the beginning of the year, with a 3.74% drop over the last five trading days, a 5.66% decline over the last 20 days, and a 6.53% decrease over the last 60 days [2]. Group 2: Company Overview - Heng Rui Medicine, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various medical fields such as autoimmune diseases, cardiovascular diseases, and pain management [2]. - The main revenue sources for Heng Rui Medicine are product sales (86.88%), licensing income (12.63%), and other income (0.49%) [2]. Group 3: Financial Performance - For the period from January to September 2025, Heng Rui Medicine reported a revenue of 23.188 billion CNY, reflecting a year-on-year growth of 14.85%, and a net profit attributable to shareholders of 5.751 billion CNY, which is a 24.50% increase compared to the previous year [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for Heng Rui Medicine was 397,300, an increase of 8.94% from the previous period, while the average circulating shares per person decreased by 8.21% to 16,058 shares [3]. - The company has distributed a total of 9.303 billion CNY in dividends since its A-share listing, with 3.568 billion CNY distributed over the last three years [4].

Core Viewpoint - Heng Rui Medicine announced that its innovative drug, SHR-1918 injection, a fully human monoclonal antibody targeting ANGPTL3, has received acceptance for its drug listing application and has been included in the priority review process for treating adult and adolescent patients aged 12 and above with homozygous familial hypercholesterolemia (HoFH) [1] Group 1 - SHR-1918 injection is independently developed by Heng Rui Medicine as a fully human anti-ANGPTL3 monoclonal antibody [1] - The mechanism of SHR-1918 involves inhibiting the activity of ANGPTL3, leading to a reduction in serum triglycerides (TG) and LDL-C levels [1]